Long-Term Outcomes after Spleen-Preserving Distal Pancreatectomy for Pancreatic Neuroendocrine Tumors: Results from the US Neuroendocrine Study Group.
Distal pancreatectomy
Pancreatic neuroendocrine tumor
Spleen
Survival
Journal
Neuroendocrinology
ISSN: 1423-0194
Titre abrégé: Neuroendocrinology
Pays: Switzerland
ID NLM: 0035665
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
10
2019
accepted:
09
02
2020
pubmed:
11
2
2020
medline:
5
10
2021
entrez:
11
2
2020
Statut:
ppublish
Résumé
The adoption of spleen-preserving distal pancreatectomy (SPDP) for malignant disease such as pancreatic neuroendocrine tumors (pNETs) has been controversial. The objective of the current study was to assess the impact of SPDP on outcomes of patients with pNETs. Patients undergoing a distal pancreatectomy for pNET between 2002 and 2016 were identified in the US Neuroendocrine Tumor Study Group database. Propensity score matching (PSM) was used to compare short- and long-term outcomes of patients undergoing SPDP versus distal pancreatectomy with splenectomy (DPS). Among 621 patients, 103 patients (16.6%) underwent an SPDP. Patients who underwent SPDP were more likely to have lower BMI (median, 27.5 [IQR 24.0-31.2] vs. 28.7 [IQR 25.7-33.6]; p = 0.005) and have undergone minimally invasive surgery (n = 56, 54.4% vs. n = 185, 35.7%; p < 0.001). After PSM, while the median total number of lymph nodes examined among patients who underwent an SPDP was lower compared with DPS (3 [IQR 1-8] vs. 9 [5-13]; p < 0.001), 5-year overall survival (OS) and recurrence-free survival (RFS) were comparable (OS: 96.8 vs. 92.0%, log-rank p = 0.21, RFS: 91.1 vs. 84.7%, log-rank p = 0.93). In addition, patients undergoing SPDP had less intraoperative blood loss (median, 100 mL [IQR 10-250] vs. 150 mL [IQR 100-400]; p = 0.001), lower incidence of serious complications (n = 13, 12.8% vs. n = 28, 27.5%; p = 0.014), and shorter length of stay (median: 5 days [IQR 4-7] vs. 6 days [IQR 5-13]; p = 0.049) compared with patients undergoing DPS. SPDP for pNET was associated with acceptable perioperative and long-term outcomes that were comparable to DPS. SPDP should be considered for patients with pNET.
Sections du résumé
BACKGROUND
The adoption of spleen-preserving distal pancreatectomy (SPDP) for malignant disease such as pancreatic neuroendocrine tumors (pNETs) has been controversial. The objective of the current study was to assess the impact of SPDP on outcomes of patients with pNETs.
METHODS
Patients undergoing a distal pancreatectomy for pNET between 2002 and 2016 were identified in the US Neuroendocrine Tumor Study Group database. Propensity score matching (PSM) was used to compare short- and long-term outcomes of patients undergoing SPDP versus distal pancreatectomy with splenectomy (DPS).
RESULTS
Among 621 patients, 103 patients (16.6%) underwent an SPDP. Patients who underwent SPDP were more likely to have lower BMI (median, 27.5 [IQR 24.0-31.2] vs. 28.7 [IQR 25.7-33.6]; p = 0.005) and have undergone minimally invasive surgery (n = 56, 54.4% vs. n = 185, 35.7%; p < 0.001). After PSM, while the median total number of lymph nodes examined among patients who underwent an SPDP was lower compared with DPS (3 [IQR 1-8] vs. 9 [5-13]; p < 0.001), 5-year overall survival (OS) and recurrence-free survival (RFS) were comparable (OS: 96.8 vs. 92.0%, log-rank p = 0.21, RFS: 91.1 vs. 84.7%, log-rank p = 0.93). In addition, patients undergoing SPDP had less intraoperative blood loss (median, 100 mL [IQR 10-250] vs. 150 mL [IQR 100-400]; p = 0.001), lower incidence of serious complications (n = 13, 12.8% vs. n = 28, 27.5%; p = 0.014), and shorter length of stay (median: 5 days [IQR 4-7] vs. 6 days [IQR 5-13]; p = 0.049) compared with patients undergoing DPS.
CONCLUSION
SPDP for pNET was associated with acceptable perioperative and long-term outcomes that were comparable to DPS. SPDP should be considered for patients with pNET.
Identifiants
pubmed: 32040951
pii: 000506399
doi: 10.1159/000506399
pmc: PMC10182897
mid: NIHMS1886975
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
129-138Subventions
Organisme : NCI NIH HHS
ID : K12 CA090625
Pays : United States
Informations de copyright
© 2020 S. Karger AG, Basel.
Références
Surgery. 2019 Jul;166(1):15-21
pubmed: 31072670
J Gastrointest Surg. 2012 Jul;16(7):1347-53
pubmed: 22528577
Surgery. 1996 Nov;120(5):885-90
pubmed: 8909526
J Clin Oncol. 2004 Dec 1;22(23):4762-71
pubmed: 15570077
Eur J Cancer. 2001 May;37(8):1014-9
pubmed: 11334727
J Gastrointest Surg. 2015 May;19(5):831-40
pubmed: 25759075
Gastroenterology. 2010 Sep;139(3):742-53, 753.e1
pubmed: 20637207
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Arch Surg. 2002 Feb;137(2):164-8
pubmed: 11822953
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
Lancet. 2011 Jul 2;378(9785):86-97
pubmed: 21474172
Cancer. 2011 Jan 15;117(2):268-75
pubmed: 20824724
Cancer Treat Rev. 2014 Apr;40(3):376-89
pubmed: 24296109
Neuroendocrinology. 2016;103(2):153-71
pubmed: 26742109
Ann Surg. 2014 Feb;259(2):197-203
pubmed: 24253141
J Am Coll Surg. 2011 Apr;212(4):651-7; discussion 657-8
pubmed: 21463805
Surgery. 1998 Feb;123(2):127-30
pubmed: 9481396
J Surg Oncol. 2019 Aug;120(2):231-240
pubmed: 31001868
J Gastroenterol. 2012 Sep;47(9):941-60
pubmed: 22886480
Ann Surg. 2021 Jul 1;274(1):e28-e35
pubmed: 31356277
Am J Epidemiol. 2010 Mar 1;171(5):624-32
pubmed: 20106935
Neuroendocrinology. 2012;95(2):120-34
pubmed: 22261872
Int J Clin Exp Med. 2015 Oct 15;8(10):17128-39
pubmed: 26770307
Ann Surg. 2011 Jun;253(6):1136-9
pubmed: 21394008
Oncotarget. 2017 May 16;8(20):33872-33883
pubmed: 28477012
JAMA Surg. 2013 Oct;148(10):932-9
pubmed: 23986355
Pancreas. 2010 Aug;39(6):825-8
pubmed: 20431423
J Surg Oncol. 2019 Dec;120(7):1080-1086
pubmed: 31468550
Cancer. 1995 Jan 15;75(2):577-83
pubmed: 7812926
J Surg Oncol. 2017 Feb;115(2):137-143
pubmed: 28133818
Pancreas. 2012 Aug;41(6):840-4
pubmed: 22781907
J Clin Oncol. 2011 Jun 10;29(17):2372-7
pubmed: 21555696
Neuroendocrinology. 2017 Feb 25;105(3):255-265
pubmed: 28237989
HPB (Oxford). 2013 Jun;15(6):403-10
pubmed: 23458666
Ann Surg Oncol. 2019 Sep;26(9):2722-2729
pubmed: 31209670
Int J Surg. 2015 Sep;21 Suppl 1:S40-3
pubmed: 26118603
Br J Surg. 2017 Mar;104(4):452-462
pubmed: 28004852